Гиперселекция пациентов при назначении анти-EGFR-антител. Первые результаты отечественного исследования

Появление новых таргетных препаратов, поставили перед нами новую проблему правильного их назначения. Селекция пациентов и рациональное использование таргетных агентов, не только позволит добиться высоких результатов в терапии, но предотвратит чрезмерного, и самое главное, не обоснованного назначения препаратов.

1. Злокачественные новообразования в России в 2022 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, О.В. Шахзадовой, И.В. Лисичниковой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2023.275 с.

2. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938–2947. https://doi.org/10.1200/JCO.2000.18.16.2938

3. Martini G., Troiani T., Cardone C., et al. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World J Gastroenterol 2017;23(26):4675–4688. https://doi.org/10.3748/wjg.v23.i26.4675

4. Shuford R.A., Cairns A.L., Moaven O. Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements Towards Individualizing the Treatment. Cancers (Basel) 2020;12(11):3481. https://doi.org/10.3390/cancers12113481

5. Venook A.P., Niedzwiecki D., Lenz H.J., et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 2017;317(23):2392–2401. https://doi.org/10.1001/jama.2017.7105

6. Cremolini C., Antoniotti C., Lonardi S., et al. Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a randomized phase 2 clinical trial. JAMA Oncol 2018;4(4):529–536. https://doi.org/10.1001/jamaoncol.2017.5314

7. Van Cutsem E., Köhne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408–1417. https://doi.org/10.1056/NEJMoa0805019

8. Lindskog M., Tavelin B., Lundström S. Old age as risk indicator for poor end-of-life care quality a population-based study of cancer deaths from the Swedish Register of Palliative Care. Eur J Cancer 2015;51(10):1331–9. https://doi.org/10.1016/j.ejca.2015.04.001

9. Kim T.W., Elme A., Kusic Z., et al. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. Br J Cancer 2016;115(10):1206–1214. https://doi.org/10.1038/bjc.2016.309

10. Cianchi F., Cortesini C., Schiavone N., et al. The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin Cancer Res 2005;11(19 Pt 1):6807–15. https://doi.org/10.1158/1078-0432.CCR-05-0675

11. Douillard J.Y., Oliner K.S., Siena S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023–34. https://doi.org/10.1056/NEJMoa1305275

12. Qin S., Li J., Wang L., et al. Efficacy and tolerability of first-line cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with ras wild-type metastatic colorectal cancer: the open-label, randomized, phase III TAILOR trial. J Clin Oncol 2018;36(30):3031–3039. https://doi.org/10.1200/JCO.2018.78.3183

13. Bokemeyer C., Van Cutsem E., Rougier P., et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012;48(10):1466–75. https://doi.org/10.1016/j.ejca.2012.02.057

14. De Roock W., De Vriendt V., Normanno N., et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011;12(6):594–603. https://doi.org/10.1016/S1470-2045(10)70209-6

15. Karakas B., Bachman K.E., Park B.H. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006;94(4):455–9. https://doi.org/10.1038/sj.bjc.6602970

16. Liao X., Morikawa T., Lochhead P., et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012;18(8):2257–68. https://doi.org/10.1158/1078-0432.CCR-11-2410

17. Seymour M.T., Brown S.R., Middleton G., et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013;14(8):749–59. https://doi.org/10.1016/S1470-2045(13)70163-3

18. Morano F., Corallo S., Lonardi S., et al. Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy. J Clin Oncol 2019;37(33):3099–3110. https://doi.org/10.1200/JCO.19.01254

19. Sartore-Bianchi A., Trusolino L., Martino C., et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proofof-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17(6):738–746. https://doi.org/10.1016/S1470–2045(16)00150–9. Erratum in: Lancet Oncol 2016;17(10):e420. https://doi.org/10.1016/S1470-2045(16)30463-6

20. Watanabe J., Muro K., Shitara K., et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 2023;329(15):1271–1282. https://doi.org/10.1001/jama.2023.4428. Erratum in: JAMA 2023;329(24):2196. https://doi.org/10.1001/jama.2023.10533

21. Shitara K., Muro K., Watanabe J., et al. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer. Nat Med 2024;30(3):730–739. https://doi.org/10.1038/s41591-023-02791-w

22. Salikhova D.I., Golovicheva V.V., Fatkhudinov T.K., et al. Therapeutic efficiency of proteins secreted by glial progenitor cells in a rat model of traumatic brain injury. Int J Mol Sci 2023;24(15):12341. https://doi.org/10.3390/ijms241512341.